Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 380

1.

Temporal auto-regulation during human PU.1 locus SubTAD formation.

Schuetzmann D, Walter C, van Riel B, Kruse S, König T, Erdmann T, Tönges A, Bindels E, Weilemann A, Gebhard C, Wethmar K, Perrod C, Minderjahn J, Rehli M, Delwel R, Lenz G, Gröschel S, Dugas M, Rosenbauer F.

Blood. 2018 Oct 12. pii: blood-2018-02-834721. doi: 10.1182/blood-2018-02-834721. [Epub ahead of print]

PMID:
30315124
2.

Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.

Kessler T, Baumeier A, Brand C, Grau M, Angenendt L, Harrach S, Stalmann U, Schmidt LH, Gosheger G, Hardes J, Andreou D, Dreischalück J, Lenz G, Wardelmann E, Mesters RM, Schwöppe C, Berdel WE, Hartmann W, Schliemann C.

Transl Oncol. 2018 Dec;11(6):1271-1282. doi: 10.1016/j.tranon.2018.08.004. Epub 2018 Aug 17.

3.

FHIRChain: Applying Blockchain to Securely and Scalably Share Clinical Data.

Zhang P, White J, Schmidt DC, Lenz G, Rosenbloom ST.

Comput Struct Biotechnol J. 2018 Jul 29;16:267-278. doi: 10.1016/j.csbj.2018.07.004. eCollection 2018.

4.

A Suite of Transgenic Driver and Reporter Mouse Lines with Enhanced Brain-Cell-Type Targeting and Functionality.

Daigle TL, Madisen L, Hage TA, Valley MT, Knoblich U, Larsen RS, Takeno MM, Huang L, Gu H, Larsen R, Mills M, Bosma-Moody A, Siverts LA, Walker M, Graybuck LT, Yao Z, Fong O, Nguyen TN, Garren E, Lenz GH, Chavarha M, Pendergraft J, Harrington J, Hirokawa KE, Harris JA, Nicovich PR, McGraw MJ, Ollerenshaw DR, Smith KA, Baker CA, Ting JT, Sunkin SM, Lecoq J, Lin MZ, Boyden ES, Murphy GJ, da Costa NM, Waters J, Li L, Tasic B, Zeng H.

Cell. 2018 Jul 12;174(2):465-480.e22. doi: 10.1016/j.cell.2018.06.035.

PMID:
30007418
5.

90 Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience.

Spukti EU, Schmidt LH, Schulze A, Schliemann C, Görlich D, Wardelmann E, Hartmann W, Lenz G, Berdel WE, Kerkhoff A.

Eur J Haematol. 2018 Oct;101(4):514-521. doi: 10.1111/ejh.13138. Epub 2018 Sep 3.

PMID:
29993147
6.

Transcriptional characterization of immunological infiltrates and their relation with glioblastoma patients overall survival.

Pereira MB, Barros LRC, Bracco PA, Vigo A, Boroni M, Bonamino MH, Lenz G.

Oncoimmunology. 2018 Feb 12;7(6):e1431083. doi: 10.1080/2162402X.2018.1431083. eCollection 2018.

PMID:
29872555
7.

Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer.

Mikesch JH, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Köhler G, Lenz G, Müller-Tidow C, Berdel WE, Arteaga MF.

Eur Respir J. 2018 Jul 11;52(1). pii: 1701637. doi: 10.1183/13993003.01637-2017. Print 2018 Jul.

PMID:
29853494
8.

Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases.

Schliemann C, Kerkhoff A, Hesse P, Bröckling S, Hardes J, Streitbürger A, Andreou D, Gosheger G, Elges S, Wardelmann E, Hartmann W, Mesters R, Lenz G, Willich N, Kriz J, Eich H, Berdel WE, Kessler T.

PLoS One. 2018 May 22;13(5):e0197315. doi: 10.1371/journal.pone.0197315. eCollection 2018.

9.

Autophagy in glioma cells: An identity crisis with a clinical perspective.

Ulasov IV, Lenz G, Lesniak MS.

Cancer Lett. 2018 Aug 1;428:139-146. doi: 10.1016/j.canlet.2018.04.034. Epub 2018 Apr 27.

PMID:
29709703
10.

Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas.

Schmitz N, Lenz G, Stelljes M.

Blood. 2018 Jul 19;132(3):245-253. doi: 10.1182/blood-2018-01-791335. Epub 2018 Apr 26. Review.

PMID:
29699989
11.

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.

Schleussner N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, Durek P, Anagnostopoulos I, Hummel M, Jöhrens K, Niedobitek A, Griffin PR, Piva R, Sczakiel HL, Woessmann W, Damm-Welk C, Hinze C, Stoiber D, Gillissen B, Turner SD, Kaergel E, von Hoff L, Grau M, Lenz G, Dörken B, Scheidereit C, Kenner L, Janz M, Mathas S.

Leukemia. 2018 Sep;32(9):1994-2007. doi: 10.1038/s41375-018-0045-9. Epub 2018 Mar 28.

12.

Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.

Dunleavy K, Erdmann T, Lenz G.

Cancer Treat Rev. 2018 Apr;65:41-46. doi: 10.1016/j.ctrv.2018.01.002. Epub 2018 Feb 1. Review.

PMID:
29549872
13.

High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.

Steckel NK, Groth C, Mikesch JH, Trenschel R, Ottinger H, Kordelas L, Mueller-Tidow C, Schliemann C, Reicherts C, Albring JC, Silling G, Schmidt E, Berdel WE, Lenz G, Ditschkowski M, Beelen DW, Stelljes M.

Br J Haematol. 2018 Mar;180(6):840-853. doi: 10.1111/bjh.15137. Epub 2018 Feb 21.

PMID:
29468631
14.

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development.

Gu JJ, Singh A, Xue K, Mavis C, Barth M, Yanamadala V, Lenz P, Grau M, Lenz G, Czuczman MS, Hernandez-Ilizaliturri FJ.

Oncotarget. 2017 Dec 19;9(3):4020-4033. doi: 10.18632/oncotarget.23425. eCollection 2018 Jan 9.

15.

The developing human connectome project: A minimal processing pipeline for neonatal cortical surface reconstruction.

Makropoulos A, Robinson EC, Schuh A, Wright R, Fitzgibbon S, Bozek J, Counsell SJ, Steinweg J, Vecchiato K, Passerat-Palmbach J, Lenz G, Mortari F, Tenev T, Duff EP, Bastiani M, Cordero-Grande L, Hughes E, Tusor N, Tournier JD, Hutter J, Price AN, Teixeira RPAG, Murgasova M, Victor S, Kelly C, Rutherford MA, Smith SM, Edwards AD, Hajnal JV, Jenkinson M, Rueckert D.

Neuroimage. 2018 Jun;173:88-112. doi: 10.1016/j.neuroimage.2018.01.054. Epub 2018 Jan 31.

PMID:
29409960
16.

Analysis of NTPDase2 in the cell membrane using fluorescence recovery after photobleaching (FRAP).

Kipper FC, Tamajusuku ASK, Minussi DC, Vargas JE, Battastini AMO, Kaczmarek E, Robson SC, Lenz G, Wink MR.

Cytometry A. 2018 Feb;93(2):232-238. doi: 10.1002/cyto.a.23317. Epub 2018 Jan 24.

PMID:
29364561
17.

Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.

Hershkovitz-Rokah O, Pulver D, Lenz G, Shpilberg O.

Br J Haematol. 2018 May;181(3):306-319. doi: 10.1111/bjh.15108. Epub 2018 Jan 23. Review.

PMID:
29359797
18.

Evolution of a designed protein assembly encapsulating its own RNA genome.

Butterfield GL, Lajoie MJ, Gustafson HH, Sellers DL, Nattermann U, Ellis D, Bale JB, Ke S, Lenz GH, Yehdego A, Ravichandran R, Pun SH, King NP, Baker D.

Nature. 2017 Dec 21;552(7685):415-420. doi: 10.1038/nature25157. Epub 2017 Dec 13.

19.

t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells.

Lenz G, Hamilton A, Geng S, Hong T, Kalkum M, Momand J, Kane SE, Huss JM.

Clin Cancer Res. 2018 Mar 1;24(5):1216-1226. doi: 10.1158/1078-0432.CCR-17-0824. Epub 2017 Nov 27.

PMID:
29180608
20.

CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.

Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M, Görlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Berdel WE, Schwöppe C, Hartmann W.

Lung Cancer. 2017 Nov;113:121-127. doi: 10.1016/j.lungcan.2017.09.013. Epub 2017 Sep 22.

PMID:
29110838
21.

Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.

Schmidt LH, Heitkötter B, Schulze AB, Schliemann C, Steinestel K, Trautmann M, Marra A, Hillejan L, Mohr M, Evers G, Wardelmann E, Rahbar K, Görlich D, Lenz G, Berdel WE, Hartmann W, Wiewrodt R, Huss S.

PLoS One. 2017 Oct 27;12(10):e0186280. doi: 10.1371/journal.pone.0186280. eCollection 2017.

22.

Individualisierte Therapie des metastasierten Lungenkarzinoms.

Evers G, Mohr M, Kerkhoff A, Lenz G, Wiewrodt R, Schmidt LH.

Dtsch Med Wochenschr. 2017 Oct;142(20):1531-1534. doi: 10.1055/s-0043-103471. Epub 2017 Oct 10. German.

PMID:
29017211
23.

Culture conditions defining glioblastoma cells behavior: what is the impact for novel discoveries?

Ledur PF, Onzi GR, Zong H, Lenz G.

Oncotarget. 2017 Aug 11;8(40):69185-69197. doi: 10.18632/oncotarget.20193. eCollection 2017 Sep 15. Review.

24.

Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death.

de Andrade Mello P, Bian S, Savio LEB, Zhang H, Zhang J, Junger W, Wink MR, Lenz G, Buffon A, Wu Y, Robson SC.

Oncotarget. 2017 Jun 21;8(40):67254-67268. doi: 10.18632/oncotarget.18595. eCollection 2017 Sep 15.

25.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL.

J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4.

PMID:
28976790
26.

Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.

Frick M, Bettstetter M, Bertz S, Schwarz-Furlan S, Hartmann A, Richter T, Lenze D, Hummel M, Dreyling M, Lenz G, Gaumann A.

Leuk Lymphoma. 2018 May;59(5):1260-1263. doi: 10.1080/10428194.2017.1370546. Epub 2017 Sep 3. No abstract available.

PMID:
28868954
27.

Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas.

Kipper FC, Silva AO, Marc AL, Confortin G, Junqueira AV, Neto EP, Lenz G.

Invest New Drugs. 2018 Apr;36(2):323-331. doi: 10.1007/s10637-017-0503-7. Epub 2017 Aug 29.

PMID:
28852916
28.

Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Aug 9;12(8):e0183201. doi: 10.1371/journal.pone.0183201. eCollection 2017.

29.

NEK1 kinase domain structure and its dynamic protein interactome after exposure to Cisplatin.

Melo-Hanchuk TD, Slepicka PF, Meirelles GV, Basei FL, Lovato DV, Granato DC, Pauletti BA, Domingues RR, Leme AFP, Pelegrini AL, Lenz G, Knapp S, Elkins JM, Kobarg J.

Sci Rep. 2017 Jul 14;7(1):5445. doi: 10.1038/s41598-017-05325-w.

30.

Deletion of eIF2β lysine stretches creates a dominant negative that affects the translation and proliferation in human cell line: A tool for arresting the cell growth.

Salton GD, Laurino CCFC, Mega NO, Delgado-Cañedo A, Setterblad N, Carmagnat M, Xavier RM, Cirne-Lima E, Lenz G, Henriques JAP, Laurino JP.

Cancer Biol Ther. 2017 Aug 3;18(8):560-570. doi: 10.1080/15384047.2017.1345383. Epub 2017 Jul 10.

31.

An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Angenendt L, Reuter S, Kentrup D, Benk AS, Neumann F, Hüve J, Martens AC, Schwöppe C, Kessler T, Schmidt LH, Sauer T, Brand C, Mikesch JH, Lenz G, Mesters RM, Müller-Tidow C, Hartmann W, Wardelmann E, Neri D, Berdel WE, Roesli C, Schliemann C.

Leukemia. 2018 Feb;32(2):510-519. doi: 10.1038/leu.2017.208. Epub 2017 Jun 30.

PMID:
28663580
32.

Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells.

Villodre ES, Kipper FC, Silva AO, Lenz G, Lopez PLDC.

Mol Neurobiol. 2018 May;55(5):4185-4194. doi: 10.1007/s12035-017-0611-6. Epub 2017 Jun 13.

PMID:
28612256
33.

Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Jun 12;12(6):e0177146. doi: 10.1371/journal.pone.0177146. eCollection 2017. Erratum in: PLoS One. 2017 Aug 9;12 (8):e0183201.

34.

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.

Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G; German High-Grade Lymphoma Study Group.

J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. Epub 2017 May 19.

PMID:
28525305
35.

Successful second allogeneic stem cell transplantation in a patient with T-lymphoblastic leukemia (T-ALL) relapsed as myeloid sarcoma.

Matern S, Schmidt E, Hartmann D, Schliemann C, Groth C, Lenz G, Hartmann W, Klapper W, Berdel W, Stelljes M.

Ann Hematol. 2017 Jul;96(7):1201-1203. doi: 10.1007/s00277-017-3000-3. Epub 2017 Apr 27. No abstract available.

PMID:
28451803
36.

Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.

Lenz G.

J Clin Oncol. 2017 May 1;35(13):1451-1452. doi: 10.1200/JCO.2016.72.0102. Epub 2017 Mar 14. No abstract available.

PMID:
28291389
37.

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.

Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G.

Blood. 2017 Jul 20;130(3):310-322. doi: 10.1182/blood-2016-12-758599. Epub 2017 Feb 15.

38.

Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.

Lange J, Lenz G, Burkhardt B.

Expert Rev Hematol. 2017 Feb;10(2):123-135. doi: 10.1080/17474086.2017.1271318. Epub 2016 Dec 26. Review.

PMID:
27936978
39.

The molecular pathogenesis of mantle cell lymphoma.

Vogt N, Dai B, Erdmann T, Berdel WE, Lenz G.

Leuk Lymphoma. 2017 Jul;58(7):1530-1537. doi: 10.1080/10428194.2016.1248965. Epub 2016 Nov 28. Review.

PMID:
27894215
40.

Ratiometric analysis of Acridine Orange staining in the study of acidic organelles and autophagy.

Thomé MP, Filippi-Chiela EC, Villodre ES, Migliavaca CB, Onzi GR, Felipe KB, Lenz G.

J Cell Sci. 2016 Dec 15;129(24):4622-4632. Epub 2016 Nov 14.

41.

B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.

Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G.

Blood. 2017 Jan 19;129(3):333-346. doi: 10.1182/blood-2016-05-718775. Epub 2016 Nov 18.

42.

Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years).

Pohlen M, Groth C, Sauer T, Görlich D, Mesters R, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Berdel WE, Stelljes M.

Bone Marrow Transplant. 2016 Nov;51(11):1441-1448. doi: 10.1038/bmt.2016.156. Epub 2016 Jun 13.

PMID:
27295269
43.

Roles of OCT4 in tumorigenesis, cancer therapy resistance and prognosis.

Villodre ES, Kipper FC, Pereira MB, Lenz G.

Cancer Treat Rev. 2016 Dec;51:1-9. doi: 10.1016/j.ctrv.2016.10.003. Epub 2016 Oct 14. Review.

PMID:
27788386
44.

The regrowth kinetic of the surviving population is independent of acute and chronic responses to temozolomide in glioblastoma cell lines.

Silva AO, Dalsin E, Onzi GR, Filippi-Chiela EC, Lenz G.

Exp Cell Res. 2016 Nov 1;348(2):177-183. doi: 10.1016/j.yexcr.2016.09.014. Epub 2016 Sep 23.

PMID:
27669643
45.

Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.

Stucke-Ring J, Ronnacker J, Brand C, Höltke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V, Hintelmann H, Hartmann W, Wardelmann E, Lenz G, Wünsch B, Müller-Tidow C, Mesters RM, Schwöppe C, Berdel WE.

Oncotarget. 2016 Dec 13;7(50):82458-82472. doi: 10.18632/oncotarget.12559.

46.

Hypoxic and Reoxygenated Microenvironment: Stemness and Differentiation State in Glioblastoma.

Gaelzer MM, Santos MSD, Coelho BP, de Quadros AH, Simão F, Usach V, Guma FCR, Setton-Avruj P, Lenz G, Salbego CG.

Mol Neurobiol. 2017 Oct;54(8):6261-6272. doi: 10.1007/s12035-016-0126-6. Epub 2016 Oct 6.

PMID:
27714633
47.

Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemia.

Vogt N, Heß K, Bialek R, Buerke B, Brüggemann M, Topp MS, Groth C, Berdel WE, Lenz G, Stelljes M.

Ann Hematol. 2017 Jan;96(1):151-153. doi: 10.1007/s00277-016-2837-1. Epub 2016 Oct 3. No abstract available.

PMID:
27696204
48.

The Epithelial-to-Mesenchymal Transition-Like Process in Glioblastoma: An Updated Systematic Review and In Silico Investigation.

Iser IC, Pereira MB, Lenz G, Wink MR.

Med Res Rev. 2017 Mar;37(2):271-313. doi: 10.1002/med.21408. Epub 2016 Sep 12. Review.

PMID:
27617697
49.

Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors.

Riemke P, Czeh M, Fischer J, Walter C, Ghani S, Zepper M, Agelopoulos K, Lettermann S, Gebhardt ML, Mah N, Weilemann A, Grau M, Gröning V, Haferlach T, Lenze D, Delwel R, Prinz M, Andrade-Navarro MA, Lenz G, Dugas M, Müller-Tidow C, Rosenbauer F.

EMBO J. 2016 Nov 15;35(22):2399-2416. Epub 2016 Aug 29.

50.

Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.

Wurster KD, Hummel F, Richter J, Giefing M, Hartmann S, Hansmann ML, Kreher S, Köchert K, Krappmann D, Klapper W, Hummel M, Wenzel SS, Lenz G, Janz M, Dörken B, Siebert R, Mathas S.

Leukemia. 2017 Mar;31(3):602-613. doi: 10.1038/leu.2016.238. Epub 2016 Aug 19.

Supplemental Content

Support Center